相关实验视频

Updated: Jun 29, 2025

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

Published on: August 30, 2019

在实验性严重喘和急性肺损伤中准常见的炎症媒介

Andrei Gheorghe Vicovan¹, Diana Cezarina Petrescu¹, Aurelia Cretu¹

¹Department of Morpho-Functional Sciences II-Pharmacology and Clinical Pharmacology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania.

Pharmaceuticals (Basel, Switzerland)

|March 28, 2024

概括

在喘和急性肺损伤 (ALI) 的小鼠模型中,secukinumab (SECU) 和dexamethasone (DEXA) 调节炎症反应. 这两种治疗都降低了介质蛋白-17 (IL-17) 水平,表明了潜在的治疗益处.

科学领域:

免疫学免疫学免疫学
呼吸系统医学呼吸系统医学
药理学药理学是指药理学的学科.

背景情况:

中性粒细胞和干白素-17 (IL-17) 通过促进氧化应激,驱动严重的喘和急性肺损伤 (ALI).
用脂多糖化物 (LPS) 加重的卵胺诱导喘模型用于模仿严重的呼吸系统疾病.

研究的目的:

为了评估Secukinumab (SECU) 与甲 (DEXA) 相比的疗效,在ALI叠加于恶化喘的小鼠模型中.
研究SECU和DEXA对与Th1,Th2和Th17免疫反应相关的细胞因子概况的影响.

主要方法:

卵胺诱导的喘模型在小鼠中,加剧LPS诱导ALI.
使用塞库金纽马布 (SECU) 和甲 (DEXA) 的治疗.
在支气管洗液 (BALF) 和肺组织同质物中分析细胞因子水平 (TNF-α,IFN-γ,IL-6,IL-4,IL-5,IL-13,IL-17).

主要成果:

无论是SECU还是DEXA,都显著降低了干扰素- (IFN-γ),干扰素-6 (IL-6) 和干扰素-17 (IL-17) 的水平.
DEXA增加了瘤坏死因子-α (TNF-α) 和Th2细胞因子 (IL-4,IL-5,IL-13),而SECU抑制了IL-5.
肺组织中的细胞因子变化通常与在BALF.中观察到的变化相似.

结论:

塞库金纽马布 (SECU) 显示出调节炎性细胞因子释放的能力,特别是减少Th17反应.
SECU显示出作为治疗急性肺损伤和喘加剧的条件的治疗剂的潜力.
SECU和DEXA都有效地降低了IL-17,这是一种关键的细胞因子,与严重喘和ALI的发病有关.

关键词:

介质蛋白 17 介质蛋白 17 脂聚糖类糖化物脂聚糖类糖化物这就是Secukinumab.肺部急性肺损伤是什么喘喘是一种鼠标鼠标鼠标鼠标

更多相关视频

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma-I: Introduction

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...